Glucocorticoid therapy-induced skin atrophy

Authors

  • Stefanie Schoepe,

    1. Corporate Research Business Area Inflammation, Schering AG, Berlin, Germany
    Search for more papers by this author
  • Heike Schäcke,

    1. Corporate Research Business Area Inflammation, Schering AG, Berlin, Germany
    Search for more papers by this author
  • Ekkehard May,

    1. Corporate Research Business Area Inflammation, Schering AG, Berlin, Germany
    Search for more papers by this author
  • Khusru Asadullah

    Corresponding author
    1. Corporate Research Business Area Inflammation, Schering AG, Berlin, Germany
      Priv. Doz. Dr med. Khusru Asadullah
      Head of Corp. Research Business Area Inflammation
      Schering AG
      D-13342 Berlin
      Germany
      Tel.: +49 30 468 14853
      Fax: +49 30 468 192374
      e-mail: khusru.asadullah@schering.de
    Search for more papers by this author

Priv. Doz. Dr med. Khusru Asadullah
Head of Corp. Research Business Area Inflammation
Schering AG
D-13342 Berlin
Germany
Tel.: +49 30 468 14853
Fax: +49 30 468 192374
e-mail: khusru.asadullah@schering.de

Abstract

Abstract:  Glucocorticoids (GCs) are highly effective for the topical treatment of inflammatory skin diseases. Their long-term use, however, is often accompanied by severe and partially irreversible adverse effects, with atrophy being the most prominent limitation. Progress in the understanding of GC-mediated molecular action as well as some advances in technologies to determine the atrophogenic potential of compounds has been made recently. It is likely that the detailed mechanisms of GC-induced skin atrophy will be discovered and in vitro models for the reliable prediction of atrophy will be established in the foreseeable future. This knowledge will not only facilitate safety profiling of established drugs but will also foster further drug discovery by improving compound characterization processes. New insights into GC modes of action will guide optimization strategies aiming at novel GC receptor ligands with improved effect/side effect profile.

Ancillary